Big insurers are mulling new ways to pay for Biogen's $56,000-per-year Alzheimer's drug

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 62 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 28%
  • Publisher: 51%

United States Headlines News

Business Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.

, Aduhelm, made by drugmaker Biogen, is meant to slow the progression of Alzheimer's by removing a sticky plaque that builds up in the brains of some people with the disease. It's not clear if it improves memory or cognition in patients.threaten to strain both the finances of patients and Medicare

Some experts say the price tags of Aduhelm and a pipeline of future high-cost treatments should encourage the federal government and private insurers to find new ways to pay for drugs, including arrangements in which payment is based on whether they work or not. Health insurers like Cigna and Humana are already thinking about entering into such"value-based" contracts.

Meanwhile, Humana CEO Bruce Broussard said during the company's investor day on Tuesday that while Humana hasn't yet had any detailed conversations about an outcomes-based contract for Aduhelm, it hopes to strike one up. Analysts at Capital Alpha Partners said in a research note June 8 that contracts based on patients' health outcomes are difficult to work out administratively, but Aduhelm's high-cost and potentially large patient demand could prompt the Centers for Medicare and Medicaid Services to propose one for the drug.

"It is just a question of getting enough new drugs that challenge our existing payment model," Lakdawalla said."Those have been the exception rather than the rule, but I think we're moving into an era when they will increasingly become more prevalent."

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

spoiler alert: they'll raise premiums and deductibles along with new exclusions to not pay claims

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

First patient receives controversial Biogen Alzheimer's drugA U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer's drug from Biogen Inc (BIIB.O) before Medicare had even said what it will pay for - and with some doctors upset by its approval last week. wishing him the best! imagine if this becomes a milestone in our fight against alzheimers! JonathanLanday Did they though? There’s been a lot of controversy about this approval, and three experts on the advisory panel have resigned over it.
Source: Reuters - 🏆 2. / 97 Read more »

Lizzo Just Declared A 'Big Girl Summer' And It's About Damn TimeIt ain't her fault that she's out here getting loose. in reality its not though 🤡
Source: BuzzFeed - 🏆 730. / 51 Read more »

7 big lessons I've learned from a life of moviegoing — and why I'm overjoyed to returnWarning: Justin Chang's (JustinCChang) 'return to the movies' essay is a tear-jerker. But you'll laugh too as he revisits cinematic memories and ponders post-pandemic moviegoing. JustinCChang 🎥👀🥸
Source: latimes - 🏆 11. / 82 Read more »

Diverse International Cast for Big-Budget Euro Series ‘The Swarm’ (Exclusive)The Swarm, the big-budget series based on the Frank Schätzing bestseller, has signed up a global cast of stars and up-and-comers for the 8-part environmental thriller. European actors, including Cé… WTAF are you talking about how diverse the cast is for, BEFORE you’ve even described the show!? Race baiting WANKERS!!
Source: THR - 🏆 411. / 53 Read more »

How a low-profile Senate vote could spell trouble for Big TechThe senate confirmed Lina Khan, an established critic of tech companies' market power, to a seat on the Federal Trade Commission by a 69-28 margin, picking up support from a bipartisan coalition favoring more aggressive action against Big Tech. Couple of months ago I came across a recommendation about GeorgeLinf32 wealth how he helped investors to earn lots of money with their investments. and I decided to give a trial with the little I have. Now my little has turned into something great which was not my expectation W sonaliranade A first small, albeit significant, step towards monitoring and reigning in of big tech. Congratulations linamkhan.
Source: NBCNews - 🏆 10. / 86 Read more »

17 Famous Celebrities Who Weren't Big Names In Hollywood Until After They Turned 40Saving this to my ✨inspiration✨ Pinterest board.
Source: BuzzFeed - 🏆 730. / 51 Read more »